Gumarontinib

Gumarontinib
Clinical data
Other names	Glumetinib; SCC244; SC-C244
Routes of; administration	Oral
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 6-(1-Methylpyrazol-4-yl)-1-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]sulfonylpyrazolo[4,3-b]pyridine;
CAS Number	1642581-63-2;
PubChem CID	117797905;
UNII	7JTT036WGX;
Chemical and physical data
Formula	C21H17N9O2S
Molar mass	459.49 g·mol−1

Gumarontinib is a pharmaceutical drug for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.^[1]

Gumarontinib is a selective mesenchymal–epithelial transition (MET) inhibitor.^[2]

References

^ "NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation". ecancer.org. March 10, 2023.
^ Yu, Yongfeng; et al. (2023). "Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: A multicentre, single-arm, open-label, phase 1b/2 trial". eClinicalMedicine. 59. doi:10.1016/j.eclinm.2023.101952. PMID 37096188.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] "NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation". ecancer.org. March 10, 2023.

[2] Yu, Yongfeng; et al. (2023). "Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: A multicentre, single-arm, open-label, phase 1b/2 trial". eClinicalMedicine. 59. doi:10.1016/j.eclinm.2023.101952. PMID 37096188.

[1]

[2]